Pharming Group (NASDAQ:PHAR) Issues Quarterly Earnings Results

Pharming Group (NASDAQ:PHAR) announced its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12), FiscalAI reports. The firm had revenue of $72.45 million for the quarter, compared to the consensus estimate of $92.06 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%.

Here are the key takeaways from Pharming Group’s conference call:

• RUCONEST revenue fell 15% YoY in Q1, driven mainly by an anticipated specialty?pharmacy inventory drawdown (~8%) and the planned exit from ex?U.S. markets (~3%); management says patient retention and new enrollments/prescribers are strong but expects near?term pressure in Q2 before normalization in H2.
• Joenja grew 34% YoY to $14.1M with U.S. patients up 25% (127 on paid therapy); management expects launches in Germany and Japan this year and has resubmitted a pediatric sNDA for the higher doses with an FDA decision expected in ~6 months and a second sNDA planned for summer.
• The pipeline has multiple near?term catalysts — two phase II readouts for leniolisib in broader PIDs/CVID expected later this year (encouraging expanded?access data in six severe CVID patients were presented) and completion of enrollment for the registrational study of napazimone this year with a readout next year, each described as potential billion?dollar opportunities.
• Management reiterated 2026 revenue guidance of $405–425M (8–13% growth), delivered positive Q1 operating cash flow (€2M) and €171.8M in cash/securities, and highlighted continued cost discipline (including a 20% G&A structural reduction) while funding incremental R&D — though cash declined partly due to a €12.3M lease termination payment.

Pharming Group Stock Down 26.8%

NASDAQ PHAR traded down $4.40 during trading hours on Thursday, reaching $12.00. 96,064 shares of the company’s stock were exchanged, compared to its average volume of 24,435. The company’s 50-day moving average is $16.37 and its two-hundred day moving average is $16.58. Pharming Group has a one year low of $8.69 and a one year high of $21.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59. The company has a market capitalization of $847.50 million, a price-to-earnings ratio of 1,200.00 and a beta of 0.04.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PHAR. Canaccord Genuity Group began coverage on Pharming Group in a research note on Friday, April 10th. They issued a “buy” rating and a $37.00 price target for the company. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, March 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $41.00 price target (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. Finally, Weiss Ratings raised Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, April 27th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Pharming Group has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Institutional Trading of Pharming Group

Large investors have recently bought and sold shares of the business. NewEdge Advisors LLC increased its stake in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. Millennium Management LLC bought a new stake in Pharming Group during the 4th quarter worth approximately $360,000. SmartHarvest Portfolios LLC bought a new stake in Pharming Group during the 4th quarter worth approximately $224,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Pharming Group during the 2nd quarter worth approximately $32,000. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.